UDP-glucuronosyltransferase 1-6 is a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.
This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The enzyme encoded by this gene is active on phenolic and planar compounds. Alternative splicing in the unique 5' end of this gene results in two transcript variants.
UDP-glucuronosyltransferase is also responsible for the inactivation of popular analgesic drugs, such as aspirin and acetaminophen, by glucuronidation. The loss of a functional UGT1A6 gene in certain hypercarnivores, and particularly cats, renders the animals extremely sensitive to the adverse effects of these analgesics.
Bosma PJ, Chowdhury JR, Huang TJ, et al. (1992). "Mechanisms of inherited deficiencies of multiple UDP-glucuronosyltransferase isoforms in two patients with Crigler-Najjar syndrome, type I". FASEB J.6 (10): 2859–63. PMID1634050.
Ritter JK, Crawford JM, Owens IS (1991). "Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells". J. Biol. Chem.266 (2): 1043–7. PMID1898728.
Moghrabi N, Clarke DJ, Boxer M, Burchell B (1994). "Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2". Genomics18 (1): 171–173. doi:10.1006/geno.1993.1451. PMID8276413.
Aono S, Yamada Y, Keino H, et al. (1994). "Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II". Biochem. Biophys. Res. Commun.197 (3): 1239–1244. doi:10.1006/bbrc.1993.2610. PMID8280139.
Killard AJ, O'Kennedy R, Bogan DP (1997). "Analysis of the glucuronidation of 7-hydroxycoumarin by HPLC". Journal of pharmaceutical and biomedical analysis14 (11): 1585–1590. doi:10.1016/0731-7085(96)01801-8. PMID8877866.
Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res.6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID8889548.
Ciotti M, Marrone A, Potter C, Owens IS (1998). "Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications". Pharmacogenetics7 (6): 485–495. doi:10.1097/00008571-199712000-00007. PMID9429234.
Münzel PA, Lehmköster T, Brück M, et al. (1998). "Aryl hydrocarbon receptor-inducible or constitutive expression of human UDP glucuronosyltransferase UGT1A6". Arch. Biochem. Biophys.350 (1): 72–78. doi:10.1006/abbi.1997.0485. PMID9466822.
Duffy CF, O'Kennedy R (1999). "Determination of 7-hydroxycoumarin and its glucuronide and sulphate conjugates in liver slice incubates by capillary zone electrophoresis". Journal of pharmaceutical and biomedical analysis17 (8): 1279–1284. doi:10.1016/S0731-7085(98)00015-6. PMID9800648.